Carlos Jiménez-Vicente, Paola Charry, Sandra Castaño-Diez, Francesca Guijarro, Mònica López-Guerra, Amanda Isabel Pérez-Valencia, Alexandra Martinez-Roca, Albert Cortés-Bullich, Daniel Munárriz, Maria Teresa Solano, Laura Rosiñol, Enric Carreras, Álvaro Urbano-Ispizua, Francesc Fernández-Avilés, Carmen Martinez, María Suárez-Lledó, Marina Díaz-Beyá, Montserrat Rovira, María Queralt Salas, Jordi Esteve
{"title":"对接受异基因造血干细胞移植治疗急性髓性白血病患者的欧洲白血病网络 2022 风险分类进行评估:确定预后极差的基因组。","authors":"Carlos Jiménez-Vicente, Paola Charry, Sandra Castaño-Diez, Francesca Guijarro, Mònica López-Guerra, Amanda Isabel Pérez-Valencia, Alexandra Martinez-Roca, Albert Cortés-Bullich, Daniel Munárriz, Maria Teresa Solano, Laura Rosiñol, Enric Carreras, Álvaro Urbano-Ispizua, Francesc Fernández-Avilés, Carmen Martinez, María Suárez-Lledó, Marina Díaz-Beyá, Montserrat Rovira, María Queralt Salas, Jordi Esteve","doi":"10.1111/bjh.19518","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>European LeukemiaNet refined their risk classification of acute myeloid leukaemia (AML) in 2022 (ELN 2022) according to the two new myeloid classifications published the same year. We have retrospectively assessed the prognostic value of the ELN 2022 in 120 AML patients undergoing allogeneic haematopoietic cell transplantation (allo-HCT), including 99 in first complete response (CR1) from 2011 to 2021 in our centre. Adverse risk patients (Adv) presented inferior outcome in terms of overall survival (OS) and leukaemia-free survival (LFS) (OS [<i>p</i> = 0.003], LFS [<i>p</i> = 0.02]), confirmed in multivariate analysis (hazard ratio [HR] for OS = 2.00, <i>p</i> = 0.037). These results were also seen in patients allografted in CR1. Further analysis identified a subgroup named adverse-plus (AdvP), including complex karyotype, <i>MECOM(EVI1)</i> rearrangements and <i>TP53</i> mutations, with worse outcomes than the rest of groups of patients, including the Adv (HR for OS: 3.14, <i>p</i> < 0.001, HR for LFS: 3.36, <i>p</i> < 0.001), with higher 2-year cumulative incidence of relapse (<i>p</i> < 0.001). Notably, within this analysis, the outcome of Adv and intermediate patients were similar. These findings highlight the prognostic value of ELN 2022 in patients undergoing allo-HCT, which can be improved by the recognition of a poor genetic subset (AdvP) within the Adv risk group.</p>\n </div>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":null,"pages":null},"PeriodicalIF":5.1000,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19518","citationCount":"0","resultStr":"{\"title\":\"Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group\",\"authors\":\"Carlos Jiménez-Vicente, Paola Charry, Sandra Castaño-Diez, Francesca Guijarro, Mònica López-Guerra, Amanda Isabel Pérez-Valencia, Alexandra Martinez-Roca, Albert Cortés-Bullich, Daniel Munárriz, Maria Teresa Solano, Laura Rosiñol, Enric Carreras, Álvaro Urbano-Ispizua, Francesc Fernández-Avilés, Carmen Martinez, María Suárez-Lledó, Marina Díaz-Beyá, Montserrat Rovira, María Queralt Salas, Jordi Esteve\",\"doi\":\"10.1111/bjh.19518\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <p>European LeukemiaNet refined their risk classification of acute myeloid leukaemia (AML) in 2022 (ELN 2022) according to the two new myeloid classifications published the same year. We have retrospectively assessed the prognostic value of the ELN 2022 in 120 AML patients undergoing allogeneic haematopoietic cell transplantation (allo-HCT), including 99 in first complete response (CR1) from 2011 to 2021 in our centre. Adverse risk patients (Adv) presented inferior outcome in terms of overall survival (OS) and leukaemia-free survival (LFS) (OS [<i>p</i> = 0.003], LFS [<i>p</i> = 0.02]), confirmed in multivariate analysis (hazard ratio [HR] for OS = 2.00, <i>p</i> = 0.037). These results were also seen in patients allografted in CR1. Further analysis identified a subgroup named adverse-plus (AdvP), including complex karyotype, <i>MECOM(EVI1)</i> rearrangements and <i>TP53</i> mutations, with worse outcomes than the rest of groups of patients, including the Adv (HR for OS: 3.14, <i>p</i> < 0.001, HR for LFS: 3.36, <i>p</i> < 0.001), with higher 2-year cumulative incidence of relapse (<i>p</i> < 0.001). Notably, within this analysis, the outcome of Adv and intermediate patients were similar. These findings highlight the prognostic value of ELN 2022 in patients undergoing allo-HCT, which can be improved by the recognition of a poor genetic subset (AdvP) within the Adv risk group.</p>\\n </div>\",\"PeriodicalId\":135,\"journal\":{\"name\":\"British Journal of Haematology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2024-05-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19518\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Journal of Haematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/bjh.19518\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Haematology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bjh.19518","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group
European LeukemiaNet refined their risk classification of acute myeloid leukaemia (AML) in 2022 (ELN 2022) according to the two new myeloid classifications published the same year. We have retrospectively assessed the prognostic value of the ELN 2022 in 120 AML patients undergoing allogeneic haematopoietic cell transplantation (allo-HCT), including 99 in first complete response (CR1) from 2011 to 2021 in our centre. Adverse risk patients (Adv) presented inferior outcome in terms of overall survival (OS) and leukaemia-free survival (LFS) (OS [p = 0.003], LFS [p = 0.02]), confirmed in multivariate analysis (hazard ratio [HR] for OS = 2.00, p = 0.037). These results were also seen in patients allografted in CR1. Further analysis identified a subgroup named adverse-plus (AdvP), including complex karyotype, MECOM(EVI1) rearrangements and TP53 mutations, with worse outcomes than the rest of groups of patients, including the Adv (HR for OS: 3.14, p < 0.001, HR for LFS: 3.36, p < 0.001), with higher 2-year cumulative incidence of relapse (p < 0.001). Notably, within this analysis, the outcome of Adv and intermediate patients were similar. These findings highlight the prognostic value of ELN 2022 in patients undergoing allo-HCT, which can be improved by the recognition of a poor genetic subset (AdvP) within the Adv risk group.
期刊介绍:
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.